Lamotrigine Bioequivalence

Summary

Lamotrigine Bioequivalence is a clinical trial^[1].

Key Facts

• Lamotrigine Bioequivalence is in the country of United States^[2].
• Lamotrigine Bioequivalence's instance of is recorded as clinical trial^[3].
• Lamotrigine Bioequivalence's start time is recorded as +2012-05-31T00:00:00Z^[4].
• Lamotrigine Bioequivalence's end time is recorded as +2013-10-31T00:00:00Z^[5].
• Lamotrigine Bioequivalence's main subject is recorded as epilepsy^[6].
• Lamotrigine Bioequivalence's number of participants is recorded as {'unit': '1', 'amount': '+34'}^[7].
• Lamotrigine Bioequivalence's title is recorded as Evaluation of Bioequivalence of Lamotrigine Tablets in Epileptic Patients^[8].
• Lamotrigine Bioequivalence's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[9].
• Lamotrigine Bioequivalence's ClinicalTrials.gov ID is recorded as NCT01995825^[10].
• Lamotrigine Bioequivalence's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+65'}^[11].
• Lamotrigine Bioequivalence's research intervention is recorded as lamotrigine^[12].
• Lamotrigine Bioequivalence's clinical trial phase is recorded as phase IV clinical trial^[13].
• Lamotrigine Bioequivalence's research site is recorded as University of Maryland^[14].
• Lamotrigine Bioequivalence's research subject recruitment status is recorded as completed^[15].
• Lamotrigine Bioequivalence's study type is recorded as interventional study^[16].